Principal Financial Group Inc. Purchases 82,953 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Principal Financial Group Inc. increased its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 67.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 205,864 shares of the company's stock after acquiring an additional 82,953 shares during the quarter. Principal Financial Group Inc. owned approximately 0.35% of Twist Bioscience worth $9,301,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Signaturefd LLC boosted its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after acquiring an additional 306 shares during the last quarter. EdgeRock Capital LLC purchased a new position in Twist Bioscience in the 2nd quarter valued at $43,000. Blue Trust Inc. lifted its holdings in Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after acquiring an additional 1,136 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Twist Bioscience in the second quarter valued at $61,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after buying an additional 381 shares during the last quarter.

Insider Buying and Selling at Twist Bioscience

In related news, insider Dennis Cho sold 1,507 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00. Following the sale, the insider now owns 91,163 shares in the company, valued at approximately $4,375,824. This represents a 1.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert Chess sold 3,600 shares of the business's stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $47.26, for a total value of $170,136.00. Following the transaction, the director now directly owns 21,641 shares in the company, valued at approximately $1,022,753.66. This trade represents a 14.26 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,118 shares of company stock valued at $4,391,151 in the last 90 days. 3.92% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of research reports. JPMorgan Chase & Co. boosted their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a report on Monday, August 5th. Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a research report on Tuesday. Barclays dropped their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research report on Tuesday. Leerink Partners upped their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. Finally, Robert W. Baird upped their price objective on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $51.78.

Twist Bioscience Trading Down 1.3 %

TWST stock traded down $0.55 during mid-day trading on Tuesday, hitting $40.88. The stock had a trading volume of 438,615 shares, compared to its average volume of 950,185. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of -10.74 and a beta of 1.78. The company has a fifty day moving average of $43.98 and a 200 day moving average of $46.18. Twist Bioscience Co. has a 1-year low of $23.00 and a 1-year high of $60.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.